Published in J Virol on December 01, 1991
Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol (1995) 9.02
Pathogenesis of human immunodeficiency virus infection. Microbiol Rev (1993) 5.88
Quantitation of human immunodeficiency virus type 1 infection kinetics. J Virol (1993) 5.17
Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol (1992) 4.86
HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci U S A (2002) 3.28
Human immunodeficiency virus type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression. J Virol (1994) 3.01
Functional role of the V1/V2 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 in infection of primary macrophages and soluble CD4 neutralization. J Virol (1994) 2.52
Fusogenic selectivity of the envelope glycoprotein is a major determinant of human immunodeficiency virus type 1 tropism for CD4+ T-cell lines vs. primary macrophages. Proc Natl Acad Sci U S A (1995) 2.46
Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated. J Virol (1994) 2.40
Feline immunodeficiency virus: an interesting model for AIDS studies and an important cat pathogen. Clin Microbiol Rev (1995) 2.06
Unusual polymorphisms in human immunodeficiency virus type 1 associated with nonprogressive infection. J Virol (2000) 2.04
Increase in soluble CD4 binding to and CD4-induced dissociation of gp120 from virions correlates with infectivity of human immunodeficiency virus type 1. J Virol (1994) 1.92
Evidence that the structural conformation of envelope gp120 affects human immunodeficiency virus type 1 infectivity, host range, and syncytium-forming ability. J Virol (1993) 1.81
A pathogenic threshold of virus load defined in simian immunodeficiency virus- or simian-human immunodeficiency virus-infected macaques. J Virol (1998) 1.79
Human immunodeficiency viruses regulated by alternative trans-activators: genetic evidence for a novel non-transcriptional function of Tat in virion infectivity. EMBO J (1994) 1.78
Lower mutation rate of bovine leukemia virus relative to that of spleen necrosis virus. J Virol (1994) 1.76
Multiple extracellular domains of CCR-5 contribute to human immunodeficiency virus type 1 entry and fusion. J Virol (1997) 1.75
Mapping of epitopes exposed on intact human immunodeficiency virus type 1 (HIV-1) virions: a new strategy for studying the immunologic relatedness of HIV-1. J Virol (1998) 1.75
Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection. J Virol (1993) 1.68
Both the V2 and V3 regions of the human immunodeficiency virus type 1 surface glycoprotein functionally interact with other envelope regions in syncytium formation. J Virol (1993) 1.50
Infection of primary human microglia and monocyte-derived macrophages with human immunodeficiency virus type 1 isolates: evidence of differential tropism. J Virol (1996) 1.47
Human immunodeficiency virus type 1 envelope gp120 is cleaved after incubation with recombinant soluble CD4. J Virol (1993) 1.38
Bovine leukemia virus, an animal model for the study of intrastrain variability. J Virol (1993) 1.38
Changes in both gp120 and gp41 can account for increased growth potential and expanded host range of human immunodeficiency virus type 1. J Virol (1992) 1.35
Identification of a linear neutralization site within the third variable region of the feline immunodeficiency virus envelope. J Virol (1993) 1.28
Isolation of human immunodeficiency virus type 1 (HIV-1) RNA from feces by a simple method and difference between HIV-1 subpopulations in feces and serum. J Clin Microbiol (1995) 1.25
Biological, molecular, and structural analysis of a cytopathic variant from a molecularly cloned simian immunodeficiency virus. J Virol (1994) 1.24
beta-chemokines and neutralizing antibody titers correlate with sterilizing immunity generated in HIV-1 vaccinated macaques. Proc Natl Acad Sci U S A (1998) 1.20
HIV-1 macrophage tropism is determined at multiple levels of the viral replication cycle. J Clin Invest (1994) 1.18
Differential regulation of cellular tropism and sensitivity to soluble CD4 neutralization by the envelope gp120 of human immunodeficiency virus type 1. J Virol (1994) 1.15
Effect of amino acid substitutions on calmodulin binding and cytolytic properties of the LLP-1 peptide segment of human immunodeficiency virus type 1 transmembrane protein. J Virol (1995) 1.08
Effect of soluble CD4 on exposure of epitopes on primary, intact, native human immunodeficiency virus type 1 virions of different genetic clades. J Virol (2001) 1.08
Evolution of subtype C HIV-1 Env in a slowly progressing Zambian infant. Retrovirology (2005) 1.07
The cytopathicity of a simian immunodeficiency virus Mne variant is determined by mutations in Gag and Env. J Virol (1997) 1.07
Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection. J Virol (1999) 1.04
Recombinant human immunodeficiency virus type 1 genomes with tat unconstrained by overlapping reading frames reveal residues in Tat important for replication in tissue culture. J Virol (1996) 1.04
Distinguishing features of an infectious molecular clone of the highly divergent and noncytopathic human immunodeficiency virus type 2 UC1 strain. J Virol (1993) 1.03
Exposure to bacterial products renders macrophages highly susceptible to T-tropic HIV-1. J Clin Invest (1998) 1.01
Coreceptor specificity of temporal variants of simian immunodeficiency virus Mne. J Virol (1999) 0.95
Interaction of human immunodeficiency virus type 1 Tat with a unique site of TFIID inhibits negative cofactor Dr1 and stabilizes the TFIID-TFIIA complex. J Virol (1996) 0.95
Evidence for viral virulence as a predominant factor limiting human immunodeficiency virus vaccine efficacy. J Virol (2000) 0.93
A naturally occurring substitution in human immunodeficiency virus Tat increases expression of the viral genome. J Virol (2003) 0.93
The envelope gp120 gene of human immunodeficiency virus type 1 determines the rate of CD4-positive T-cell depletion in SCID mice engrafted with human peripheral blood leukocytes. J Virol (1996) 0.92
The basic RNA-binding domain of HIV-2 Tat contributes to preferential trans-activation of a TAR2-containing LTR. Nucleic Acids Res (1992) 0.91
Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: evidence for viral clearance. J Virol (1999) 0.90
RANTES and MCP-3 inhibit the replication of T-cell-tropic human immunodeficiency virus type 1 strains (SF-2, MN, and HE). J Virol (1997) 0.90
Bystander killing during avian leukosis virus subgroup B infection requires TVB(S3) signaling. J Virol (2003) 0.88
The human immunodeficiency virus (HIV) gag gene product p18 is responsible for enhanced fusogenicity and host range tropism of the highly cytopathic HIV-1-NDK strain. J Virol (1992) 0.88
Replication of macrophage-tropic and T-cell-tropic strains of human immunodeficiency virus type 1 is augmented by macrophage-endothelial cell contact. J Virol (1995) 0.87
Evolution of broad host range in retroviruses leads to cell death mediated by highly cytopathic variants. J Virol (2006) 0.86
The RRE of human immunodeficiency virus type 1 contributes to cell-type-specific viral tropism. J Virol (1993) 0.81
Jembrana disease virus Tat can regulate human immunodeficiency virus (HIV) long terminal repeat-directed gene expression and can substitute for HIV Tat in viral replication. J Virol (2000) 0.79
Envelope glycoprotein (gp120) from HIV-1 enhances Mycobacterium avium growth in human bronchoalveolar macrophages; an effect mediated by enhanced prostaglandin synthesis. Clin Exp Immunol (1994) 0.77
Evolution of the human immunodeficiency virus type 2 envelope gene in preimmunized and persistently infected rhesus macaques. J Virol (1994) 0.76
Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science (1984) 15.82
Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1. Science (1987) 13.52
Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor. Cell (1987) 11.56
Nucleotide sequence and expression of an AIDS-associated retrovirus (ARV-2). Science (1985) 10.97
Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science (1985) 10.71
Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retrovirus of AIDS. Cell (1986) 10.70
Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science (1991) 10.53
HIV-1 tropism for mononuclear phagocytes can be determined by regions of gp120 outside the CD4-binding domain. Nature (1990) 9.72
Biologic features of HIV-1 that correlate with virulence in the host. Science (1988) 9.06
Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene. Nature (1991) 8.80
Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. Proc Natl Acad Sci U S A (1988) 8.40
Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates. J Virol (1989) 8.32
Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding. J Virol (1990) 7.85
Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection. Lancet (1986) 7.09
HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope. Science (1986) 6.33
Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: prediction of antigenic epitopes in conserved and variable regions. J Virol (1987) 6.20
Characterization of the AIDS-associated retrovirus reverse transcriptase and optimal conditions for its detection in virions. Virology (1985) 6.08
Identification of a determinant within the human immunodeficiency virus 1 surface envelope glycoprotein critical for productive infection of primary monocytes. Proc Natl Acad Sci U S A (1991) 5.26
Extensive variation of human immunodeficiency virus type-1 in vivo. Nature (1988) 5.02
Distinct replicative and cytopathic characteristics of human immunodeficiency virus isolates. J Virol (1988) 4.96
Viral determinants of human immunodeficiency virus type 1 T-cell or macrophage tropism, cytopathogenicity, and CD4 antigen modulation. J Virol (1990) 4.85
Detection of a fusion peptide sequence in the transmembrane protein of human immunodeficiency virus. Cell (1987) 4.84
Identification of the principal neutralizing determinant of human immunodeficiency virus type 1 as a fusion domain. J Virol (1991) 4.37
Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4. J Virol (1988) 4.13
Immunoassay for the detection and quantitation of infectious human retrovirus, lymphadenopathy-associated virus (LAV). J Immunol Methods (1985) 3.91
Effects of anti-gp120 monoclonal antibodies on CD4 receptor binding by the env protein of human immunodeficiency virus type 1. J Virol (1988) 3.88
The V3 loops of the HIV-1 and HIV-2 surface glycoproteins contain proteolytic cleavage sites: a possible function in viral fusion? AIDS Res Hum Retroviruses (1991) 3.78
Structural and functional characterization of human immunodeficiency virus tat protein. J Virol (1989) 3.57
Interaction between the human T-cell lymphotropic virus type IIIB envelope glycoprotein gp120 and the surface antigen CD4: role of carbohydrate in binding and cell fusion. Proc Natl Acad Sci U S A (1987) 3.47
Isolates of human immunodeficiency virus type 1 from the brain may constitute a special group of the AIDS virus. Proc Natl Acad Sci U S A (1989) 3.31
Differential ability of human immunodeficiency virus isolates to productively infect human cells. J Immunol (1987) 3.19
Molecular cloning of AIDS-associated retrovirus. Nature (1985) 3.16
Transactivation induced by human T-lymphotropic virus type III (HTLV III) maps to a viral sequence encoding 58 amino acids and lacks tissue specificity. Virology (1986) 3.15
Host range mutant of human immunodeficiency virus type 1: modification of cell tropism by a single point mutation at the neutralization epitope in the env gene. J Virol (1991) 3.07
Human immunodeficiency virus type 1 cellular host range, replication, and cytopathicity are linked to the envelope region of the viral genome. J Virol (1990) 2.72
Multiple functional domains of Tat, the trans-activator of HIV-1, defined by mutational analysis. Nucleic Acids Res (1989) 2.72
Functional interaction of constant and variable domains of human immunodeficiency virus type 1 gp120. J Virol (1989) 2.60
Functional domains required for tat-induced transcriptional activation of the HIV-1 long terminal repeat. EMBO J (1988) 2.57
Involvement of tryptase-related cellular protease(s) in human immunodeficiency virus type 1 infection. FEBS Lett (1989) 2.34
Differences in cytopathogenicity and host cell range among infectious molecular clones of human immunodeficiency virus type 1 simultaneously isolated from an individual. J Virol (1988) 2.24
Expression of membrane-associated and secreted variants of gp160 of human immunodeficiency virus type 1 in vitro and in continuous cell lines. J Virol (1988) 2.16
The viral envelope gene is involved in macrophage tropism of a human immunodeficiency virus type 1 strain isolated from brain tissue. J Virol (1990) 2.04
Effects of a highly basic region of human immunodeficiency virus Tat protein on nucleolar localization. J Virol (1990) 1.89
Replicative capacity, cytopathic effect and cell tropism of HIV. AIDS (1989) 1.83
Sequence similarities between human immunodeficiency virus gp41 and paramyxovirus fusion proteins. AIDS Res Hum Retroviruses (1987) 1.82
Model for intracellular folding of the human immunodeficiency virus type 1 gp120. J Virol (1989) 1.70
MT-4 plaque formation can distinguish cytopathic subtypes of the human immunodeficiency virus (HIV). Virology (1988) 1.64
A chink in HIV's armour? Nature (1990) 1.56
A neutralizing epitope of human immunodeficiency virus type 1 has homologous amino acid sequences with the active site of inter-alpha-trypsin inhibitor. Int Immunol (1989) 1.31
Altered host range of HIV-1 after passage through various human cell types. Virology (1991) 1.13
Integration and expression of several molecular forms of Rous sarcoma virus DNA used for transfection of mouse cells. Mol Cell Biol (1984) 1.12
Reduction in CD4 binding affinity associated with removal of a single glycosylation site in the external glycoprotein of HIV-2. Virology (1991) 1.12
The N-terminal 31 amino acids of human immunodeficiency virus type 1 envelope protein gp120 contain a potential gp41 contact site. J Virol (1991) 1.11
Generation of hybrid human immunodeficiency virus utilizing the cotransfection method and analysis of cellular tropism. J Virol (1991) 1.10
HIV genome variability in vivo. AIDS (1989) 1.04
HIV heterogeneity and viral pathogenesis. AIDS (1988) 0.99
Biological and molecular features of HIV-1 related to tissue tropism. AIDS (1990) 0.91
Antigenic variation in HIV. AIDS (1990) 0.86
Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. Science (1984) 15.82
Nucleotide sequence and expression of an AIDS-associated retrovirus (ARV-2). Science (1985) 10.97
CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science (1986) 9.17
Biologic features of HIV-1 that correlate with virulence in the host. Science (1988) 9.06
Macrophage and T cell-line tropisms of HIV-1 are determined by specific regions of the envelope gp120 gene. Nature (1991) 8.80
Sexual practices and risk of infection by the human immunodeficiency virus. The San Francisco Men's Health Study. JAMA (1987) 7.24
Xenotropic viruses: murine leukemia viruses associated with NIH Swiss, NZB, and other mouse strains. Science (1973) 7.12
Characterization of the AIDS-associated retrovirus reverse transcriptase and optimal conditions for its detection in virions. Virology (1985) 6.08
The San Francisco Men's Health Study: III. Reduction in human immunodeficiency virus transmission among homosexual/bisexual men, 1982-86. Am J Public Health (1987) 5.78
Mutational analysis of the human immunodeficiency virus: the orf-B region down-regulates virus replication. Proc Natl Acad Sci U S A (1987) 5.65
Viral determinants of human immunodeficiency virus type 1 T-cell or macrophage tropism, cytopathogenicity, and CD4 antigen modulation. J Virol (1990) 4.85
Herpes-like sequences in HIV-infected and uninfected Kaposi's sarcoma patients. Science (1995) 4.51
Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med (2001) 4.42
Human immunodeficiency viruses. Science (1986) 4.34
AIDS-associated retroviruses (ARV) can productively infect other cells besides human T helper cells. Virology (1985) 4.30
Infectious human herpesvirus 8 in a healthy North American blood donor. Lancet (1997) 3.93
Condoms prevent transmission of AIDS-associated retrovirus. JAMA (1986) 3.78
Sequence of 3,687 nucleotides from the 3' end of Sendai virus genome RNA and the predicted amino acid sequences of viral NP, P and C proteins. Nucleic Acids Res (1983) 3.62
Antibodies to butyrate-inducible antigens of Kaposi's sarcoma-associated herpesvirus in patients with HIV-1 infection. N Engl J Med (1996) 3.61
Antibodies to human herpesvirus type 8 in the general population and in Kaposi's sarcoma patients. Lancet (1996) 3.54
Small amino acid changes in the V3 hypervariable region of gp120 can affect the T-cell-line and macrophage tropism of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A (1992) 3.42
Initiation of Sendai virus multiplication from transfected cDNA or RNA with negative or positive sense. Genes Cells (1996) 3.41
High prevalence of antibodies to acquired immune deficiency syndrome (AIDS)-associated retrovirus (ARV) in AIDS and related conditions but not in other disease states. Proc Natl Acad Sci U S A (1985) 3.35
Isolates of human immunodeficiency virus type 1 from the brain may constitute a special group of the AIDS virus. Proc Natl Acad Sci U S A (1989) 3.31
Recovery of AIDS-associated retroviruses from patients with AIDS or AIDS-related conditions and from clinically healthy individuals. J Infect Dis (1985) 3.31
Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV). Proc Natl Acad Sci U S A (1995) 3.23
Human immunodeficiency virus detected in bowel epithelium from patients with gastrointestinal symptoms. Lancet (1988) 3.21
Differential ability of human immunodeficiency virus isolates to productively infect human cells. J Immunol (1987) 3.19
Molecular cloning of AIDS-associated retrovirus. Nature (1985) 3.16
Human immunodeficiency virus can productively infect cultured human glial cells. Proc Natl Acad Sci U S A (1987) 3.14
Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients. Blood (2001) 3.00
Isolation of AIDS-associated retroviruses from cerebrospinal fluid and brain of patients with neurological symptoms. Lancet (1985) 2.88
Human lymphoblastoid lines from lymph node and spleen. Cancer (1968) 2.85
Demonstration of biological activity of a murine leukemia virus of New Zealand black mice. Science (1970) 2.79
Indirect immunofluorescence tests with sera from African children and cultured Burkitt lymphoma cells. J Bacteriol (1966) 2.79
Human immunodeficiency virus type 1 cellular host range, replication, and cytopathicity are linked to the envelope region of the viral genome. J Virol (1990) 2.72
The San Francisco Men's Health Study: continued decline in HIV seroconversion rates among homosexual/bisexual men. Am J Public Health (1988) 2.69
Human immunodeficiency virus can infect CD4-negative human fibroblastoid cells. Proc Natl Acad Sci U S A (1989) 2.66
Determination of the complete nucleotide sequence of the Sendai virus genome RNA and the predicted amino acid sequences of the F, HN and L proteins. Nucleic Acids Res (1986) 2.60
Persistent noncytopathic infection of normal human T lymphocytes with AIDS-associated retrovirus. Science (1985) 2.58
Functional role of the V1/V2 region of human immunodeficiency virus type 1 envelope glycoprotein gp120 in infection of primary macrophages and soluble CD4 neutralization. J Virol (1994) 2.52
Human immunodeficiency virus type 1 Nef associates with a cellular serine kinase in T lymphocytes. Proc Natl Acad Sci U S A (1994) 2.48
Isolation of AIDS-associated retrovirus from genital secretions of women with antibodies to the virus. Lancet (1986) 2.43
Clinical, immunologic, and serologic findings in men at risk for acquired immunodeficiency syndrome. The San Francisco Men's Health Study. JAMA (1987) 2.43
Studies with hydroxyurea. I. The reversible inhibition of bacterial DNA synthesis and the effect of hydroxyurea on the bactericidal action of streptomycin. Biochim Biophys Acta (1966) 2.42
CD8+ cell anti-HIV activity correlates with the clinical state of the infected individual. J Clin Invest (1991) 2.40
The Fc and not CD4 receptor mediates antibody enhancement of HIV infection in human cells. Science (1989) 2.40
RNA packaging signal of human immunodeficiency virus type 1. Virology (1992) 2.38
Identification of human immunodeficiency virus subtypes with distinct patterns of sensitivity to serum neutralization. Proc Natl Acad Sci U S A (1988) 2.37
AIDS retrovirus (ARV-2) clone replicates in transfected human and animal fibroblasts. Science (1986) 2.34
A diffusible lymphokine produced by CD8+ T lymphocytes suppresses HIV replication. Immunology (1989) 2.33
Risk of transmitting the human immunodeficiency virus, cytomegalovirus, and hepatitis B virus to health care workers exposed to patients with AIDS and AIDS-related conditions. J Infect Dis (1987) 2.32
CD8+ T cells suppress human immunodeficiency virus replication by inhibiting viral transcription. Proc Natl Acad Sci U S A (1995) 2.27
Differential effects of nef on HIV replication: implications for viral pathogenesis in the host. Science (1989) 2.25
Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc Natl Acad Sci U S A (1999) 2.17
Infection by the retrovirus associated with the acquired immunodeficiency syndrome. Clinical, biological, and molecular features. Ann Intern Med (1985) 2.15
Autoimmunity and neoplasia. The possible role of C-type viruses. Am J Clin Pathol (1974) 2.09
The viral envelope gene is involved in macrophage tropism of a human immunodeficiency virus type 1 strain isolated from brain tissue. J Virol (1990) 2.04
Murine xenotropic type C viruses I. Distribution and further characterization of the virus in NZB mice. J Virol (1975) 2.02
Virus-specific neutralization by a soluble non-immunoglobulin factor found naturally in normal mouse sera. Proc Natl Acad Sci U S A (1975) 2.01
Oligomeric organization of gp120 on infectious human immunodeficiency virus type 1 particles. J Virol (1990) 2.00
Prevalence of antibodies to AIDS-associated retrovirus in single men in San Francisco. Lancet (1985) 1.98
Rapid loss of CD4+ T cells in human-PBL-SCID mice by noncytopathic HIV isolates. Science (1993) 1.97
Chronic fatigue syndrome: clinical condition associated with immune activation. Lancet (1991) 1.92
Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals. J Virol (1990) 1.90
An activated CD8+ T cell phenotype correlates with anti-HIV activity and asymptomatic clinical status. Clin Immunol Immunopathol (1993) 1.89
Patterns of antibody response in individuals infected with the human immunodeficiency virus. J Infect Dis (1987) 1.86
Differential antibody responses of individuals infected with AIDS-associated retroviruses surveyed using the viral core antigen p25gag expressed in bacteria. Virology (1986) 1.81
X inactivation in the mouse embryo deficient for Dnmt1: distinct effect of hypomethylation on imprinted and random X inactivation. Dev Biol (2000) 1.80
Distinct biological and serological properties of human immunodeficiency viruses from the brain. Ann Neurol (1988) 1.79
Optimal conditions for recovery of the human immunodeficiency virus from peripheral blood mononuclear cells. J Clin Microbiol (1988) 1.78
Xenotropic type C viruses. Curr Top Microbiol Immunol (1978) 1.78
CD8+ cell anti-HIV activity: nonlytic suppression of virus replication. AIDS Res Hum Retroviruses (1992) 1.75
Inhibition of human immunodeficiency virus replication in acutely infected CD4+ cells by CD8+ cells involves a noncytotoxic mechanism. J Virol (1991) 1.72
Characterization of a noncytopathic HIV-2 strain with unusual effects on CD4 expression. Science (1988) 1.72
The Smad4 activation domain (SAD) is a proline-rich, p300-dependent transcriptional activation domain. J Biol Chem (2000) 1.70
Effect of cytokines on HIV replication in CD4+ lymphocytes: lack of identity with the CD8+ cell antiviral factor. Cell Immunol (1994) 1.70
Expression of Fas ligand in liver metastases of human colonic adenocarcinomas. Proc Natl Acad Sci U S A (1997) 1.68
Characterization of a human Kaposi's sarcoma cell line that induces angiogenic tumors in animals. AIDS (1994) 1.68
Long-term cultivation of T-cell subsets from patients with acquired immune deficiency syndrome. Clin Immunol Immunopathol (1985) 1.65
Characterization of human immunodeficiency virus type 1 isolates from children in Romania: identification of a new envelope subtype. J Infect Dis (1994) 1.64
MT-4 plaque formation can distinguish cytopathic subtypes of the human immunodeficiency virus (HIV). Virology (1988) 1.64
Minimal risk of transmission of AIDS-associated retrovirus infection by oral-genital contact. JAMA (1986) 1.62
Sendai virus C proteins are categorically nonessential gene products but silencing their expression severely impairs viral replication and pathogenesis. Genes Cells (1998) 1.62
Host range of murine xenotropic virus: replication in avian cells. Nature (1975) 1.61
Features of HIV-1 that could influence maternal-child transmission. JAMA (1994) 1.58
Importance of the cysteine-rich carboxyl-terminal half of V protein for Sendai virus pathogenesis. J Virol (1997) 1.58
An AIDS-related cytotoxic autoantibody reacts with a specific antigen on stimulated CD4+ T cells. Nature (1987) 1.57
Recovery and inactivation of infectious retroviruses from factor VIII concentration. Lancet (1984) 1.56
A conserved domain and membrane targeting of Nef from HIV and SIV are required for association with a cellular serine kinase activity. J Biol Chem (1995) 1.53
Selective coactivation of estrogen-dependent transcription by CITED1 CBP/p300-binding protein. Genes Dev (2001) 1.53
Highly purified quiescent human peripheral blood CD4+ T cells are infectible by human immunodeficiency virus but do not release virus after activation. J Virol (1995) 1.51
Measles virus attenuation associated with transcriptional impediment and a few amino acid changes in the polymerase and accessory proteins. J Virol (1998) 1.50
Social distance from the stigmatized. A test of two theories. Soc Sci Med (1982) 1.48
HIV pathogenesis and long-term survival. AIDS (1993) 1.47
Circulating immune complexes in patients with acquired immune deficiency syndrome contain the AIDS-associated retrovirus. Clin Immunol Immunopathol (1986) 1.44
Studies of FBJ osteosarcoma virus in tissue culture. I. Biologic characteristics of the "C"-type viruses. J Natl Cancer Inst (1973) 1.43
The restricted cellular host range of human herpesvirus 8. AIDS (2000) 1.41
Further studies on a glycolipid formed from dolichyl-D-glucosyl monophosphate. Carbohydr Res (1973) 1.40